简介:AIM:Toinvestigatetheefficacyofneoadjuvantchemoradiotherapy(NACRT)forresectabilityoflocallyadvancedgastriccancer(LAGC).METHODS:BetweenNovember2007andJanuary2014,29patientswithLAGC(clinicallyT3withdistalesophagusinvasion/T4orbulkyregionalnodemetastasis)thatweretreatedwithNACRTfollowedbyD2gastrectomywereincludedinthisstudy.ResectabilitywasevaluatedwithradiologicandendoscopicexamsbeforeandafterNACRT.Usingthreedimensionalconformalradiotherapy,patientsreceived45Gy,withadailydoseof1.8Gy.Theentiretumorextentandtheregionalmetastaticlymphnodeswereincludedinthegrosstumorvolume.PatientspresentingwitharesectabletumorafterNACRTreceivedatotalorsubtotalgastrectomywithD2dissection.ThepathologictumorresponsewasevaluatedusingJapaneseGastricCancerAssociationhistologicevaluationcriteria.PostoperativemorbiditywasevaluatedusingtheNationalCancerInstitute-CommonTerminologyCriteriaforAdverseEventsversion4.0.Overallsurvival(OS)andprogression-freesurvival(PFS)rateswereestimatedusingaKaplan-Meieranalysisandcomparedusingthelog-ranktest.RESULTS:Allpatientswereassessedasunresectablecases.Twenty-fourpatients(24/29;82.8%)showedLAGConpositronemissiontomography-computedtomography(CT)andcontrast-enhancedCT,whereasfourpatients(4/29;13.8%)withvagueinvasionorabutmenttoanadjacentorganunderwentdiagnosticlaparoscopy.Onepatient(1/29;3.4%),initiallyassessedasaresectablecase,underwentan'openandclosure'afterthetumorwasfoundtobeunresectable.Abutmenttoanadjacentorgan(34.5%)wasthemostcommonreasonforNACRT.TheclinicalresponserateonemonthafterNACRTwas44.8%.AfterNACRT,69%(20/29)ofpatientshadaresectabletumor.Ofthe20patientswitharesectabletumor,18patients(62.1%)underwentaD2gastrectomy.TheR0resectionratewas94.4%andtwopatients(2/18;11.1%)showedacompleteresponse.Themedianfollow-updurationwas13.5mo.Theone-yearOSandPFS
简介:目的了解HGV/GBV-C与HCV混合感染者肝组织HGV/GBV-C相关抗原的分布状况,探讨HGV/GBV-C对肝脏的损害机制。方法以抗HGV/GBV-CNS5单克隆抗体或抗HCVNS3单克隆抗体为试剂,采用免疫组织化学方法检测肝炎病人肝组织中HGV/GBV-C、HCV相关抗原表达。结果56例肝炎病肝组织中HGV/GBV-C相关抗原表达阳性率为26.79%(15/56);HCVNS3抗原表达阳性率为39.29%(22/56)。HGV/GBV-CNS5抗原表达阳性信号主要位于肝细胞胞浆中,染色阳性细胞周围可见淋巴细胞浸润。结论肝细胞中存在HGV/GBV-C相关抗原表达,其编码产物可能作为一种靶抗原,诱发免疫病理反应,免疫损伤可能是其发病机制之一。
简介:目的:观察胶原纤维在肝癌发生发展过程中的变化及其与癌变的关系。方法饲养清洁健康BALB/c小鼠40只,以30mg/ml二乙基亚硝胺(DEN)溶液作为饮用水,建立肝癌模型。在开始喂养后的0w、4w、8w、12w、16w、20w和24w,各处死3只动物,对所取肝脏组织行石蜡包埋切片,采用天狼新红染色,对胶原纤维进行检查。通过Image-ProPlus6.0对采集的样本进行光密度积分(IOD)定量,应用SPSS16.0软件对测得的数据进行ANOVA显著性分析和Student-Newman-Keuls检验。结果小鼠在诱癌剂作用20w后肝组织发生癌变;在4w末,小鼠肝组织胶原纤维IOD为(97.610±18.640),明显低于8w末胶原纤维IOD水平[(377.054±63.668),P<0.05];在8w末,胶原纤维IOD为(377.054±63.668),明显低于12w末胶原纤维IOD[(625.875±110.846),P<0.05];在16w末,胶原纤维IOD为(847.289±53.473),显著低于20w末胶原纤维IOD[(1671.301±292.593),P<0.01];在20w末,胶原纤维IOD为(1671.301±292.593),显著低于24w末胶原纤维IOD[(3968.450±138.949),P<0.01]。结论胶原纤维在癌变的整个过程中沉积量逐渐增加,变化明显,可能与肝组织的损伤修复和癌变的扩散密切相关。
简介:目的分析胃镜诊断与活检组织病理学诊断的差异及其原因,找出造成误诊的主要原因。方法对5389例胃镜诊断与活检组织病理学检查进行对比分析,并对其中76例胃镜诊断胃癌与活检诊断有差异的病例进行胃镜、活检及手术后病理诊断三者对比分析。结果胃镜下诊断为胃癌608例(11.28%),活检诊断胃癌393例(7.29%),两者比较有显著差异P<0.05;胃镜诊为良性病变中活检证实为胃癌17例(0.36%)。76例胃镜诊断胃癌与活检标本组织病理学检查有差异的手术后病理诊断结果与胃镜及检活检结果均相差甚远。结论胃镜下准确取材是获得正确活检诊断的重要前提,取材不当是误诊的主要原因之一。活检组织病理学检查对发现早期胃癌尤其重要。
简介:AIM:Toinvestigateifanimmuneimbalancemayaccountforthedevelopmentandprogressionofchronicradiationenteritis.WeanalyzedtheTh1/Th2immuneresponseprofileearlyand6moafterfractionatedcolorectalirradiation.METHODS:Aratmodeloffractionatedcolorectalγ-irradiation(4-Gyfractions,3fractionsperweek)wasdesignedtoinvestigatetheeffectsofcumulativedoseoninflammatorymediators(cytokinesandchemo-kines)andimmuneresponse(Th1/Th2profileandim-munosuppressivemediatorIL-10)duringacute(early)responseand6moaftertheendoffractionatedirradia-tion(chronicresponse).Analyseswereperformed1dafterthecumulativedosesof16Gyand36Gyand1d,3d,and26wkafterthecumulativedoseof52Gy.RESULTS:Withoutcausinghistologicaldamage,fractionatedradiationinducedelevatedexpressionofIL-1β,TNFα,MCP-1,andiNOSindistalcolonicmucosaduringtheearlypost-irradiationphase.Atthattime,aTh2profilewasconfirmedbyexpressionofboththeTh2-specifictranscriptionfactorGATA-3andthechemokinereceptorCCR4andbysuppressionoftheTh1cytokineIFNγ/IP-10throughouttheirradiationprotocol.After6mo,despitethe2-foldreductionofiNOSandMCP-1levels,theTh2profilepersisted,asshownbya50%reductionintheexpressionoftheTh1transcriptionfactorT-bet,thechemokinereceptorCCXCR3,andtheIFNγ/STAT1pathway.Atthesametime-point,theimmuno-suppressiveIL-10/STAT3pathway,knowntoregulatetheTh1/Th2balance,wasexpressed,inirradiatedrats,atapproximatelyhalfitslevelascomparedtocontrols.ThissuppressionwasassociatedwithanoverexpressionofSOCS3,whichinhibitsthefeedbackoftheTh1polarizationandregulatesIL-10production.CONCLUSION:ColorectalirradiationinducesTh2polarization,defectiveIL-10/STAT3pathwayactivationandSOCS3overexpression.Thesechanges,inturn,maintainaimmunologicalimbalancethatpersistsinthelongterm.
简介:观察普通干扰素α-2b联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者的疗效和安全性。方法采用随机、开放、多中心对照临床试验研究,纳入87例HBeAg阳性慢性乙型肝炎患者,将其随机分为普通干扰素α-2b治疗组32例,给予注射600万单位普通干扰素α-2b,1次/隔日,疗程48w;阿德福韦酯治疗组27例,给予阿德福韦酯10mg口服,1次/d,疗程72w;和联合治疗组28例,同时给予普通干扰素α-2b,48w和阿德福韦酯72w。每隔12w检测各组患者ALT、血清HBV标志物和HBVDNA水平。结果干扰素单药治疗、阿德福韦酯单药治疗和联合治疗组患者平均年龄分别为(31.8±6.6)岁、(34.2±6.4)岁和(30.5±7.2)岁,基线HBVDNA水平分别为(7.68±1.56)log10IU/ml、(7.61±2.00)log10IU/ml和(7.80±1.79)log10IU/ml,三组患者间两指标无统计学差异(P〉0.05);三组间性别构成和基线ALT水平亦无显著统计学差异(P〉0.05);在治疗72w时,干扰素单药治疗和阿德福韦酯单药治疗患者HBeAg转阴率分别为41%和19%,HBVDNA转阴率分别为53%和63%,ALT复常率分别为63%和67%,HBsAg血清学转换率为0.0%,均显著低于联合治疗组患者(57%、89%、93%和14%,P〈0.05)。结论在病毒抑制、转氨酶复常和血清学转换率方面,普通干扰素α-2b与阿德福韦酯联合治疗HBeAg阳性慢性乙型肝炎患者72w的疗效明显优于两药单独应用的效果。
简介:目的观察乙型肝炎病毒基因型以及早期HBVDNA应答对干扰素-α2b疗效的影响。方法136例慢性乙型肝炎患者接受干扰素-α2b治疗6个月,观察治疗结束时患者乙型肝炎病毒血清标志物、HBVDNA和ALT的变化。结果在完成治疗的129例患者中,C型感染者57例,B型感染者42例,B/C感染者30例。在治疗结束时,B型患者的综合应答率为42%,优于C型28%及B/C混合型16%。多变量Logistic回归分析显示,治疗3月时HBVDNA呈现应答者,治疗结束时应答率高(HBVDNA快速应答的偏回归系数=0.801,P=0.001,优势比=4.5,优势比的95%可信区间为3.01~5.28)。结论快速病毒学应答和感染病毒的基因型可以预测干扰素-α2b治疗慢性乙型肝炎的疗效。
简介:目的:探索阿德福韦酯(ADV)在不同时期联合聚乙二醇干扰素α-2a治疗HBeAg阳性的高病毒载量的慢性乙型肝炎患者的疗效。方法28例A组患者在开始治疗时给予ADV和聚乙二醇干扰素α-2a联合治疗,29例B组患者开始只给予ADV治疗,在经过平均(11.8±3.2)w治疗使血清HBVDNA≤4lgIU/ml时,再加入聚乙二醇干扰素α-2a治疗,两组均治疗48w。结果两组基线HBsAg定量分别为(4583.2±1749.3)IU/ml和(4620.3±1812.4)IU/ml,差异无统计学意义(P>0.05),治疗结束时分别为[(759.4±72.3)IU/ml和(467.6±56.9)IU/ml,P±0.05];A组HBsAg血清转换率和HBeAg血清转换率分别为7.1%和35.7%,显著低于B组的(20.7%和62.1%,P±0.05);两组ALT复常率和HBVDNA阴转率无显著性相差(P&gt;0.05)。结论对于HBeAg阳性的高病毒载量的慢性乙型肝炎患者,先经ADV治疗降低HBVDNA载量后再联合聚乙二醇干扰素α-2a治疗,可能经济、有效。
简介:Ithasbeenfoundthatexpressionof15-lipoxygenasc-1(15-LOX-1)anditsmainproduct,13-C-hydroxyoctadecadienoicacid(13-S-HODE),aredecreasedinhumancolorectalandesophagealcancersandthatnonsteroidalanti-inflammatorydrugs(NSAIDs)cantherspeuticallyinduce15-LOC-1expressiontotriggerapoptosisinthosecancercellsindependentlyCOX-2.WefoundthataspecificCOX-2inhibitorSC-236similarlyinduceapoptosisingastriccancercells,althoughthemechanismsoftheseeffectsremaintobedefined.Inthepresentstudy,wetestedwhetherSC-236inducedapoptosisthroughup-regulationof15-LOX-1ingastriccancercells.Wefoundthat,(a)SC-236inhibitedgrowthofgastriccancercellsmainlybyapoptosisinduced;(b)SC-236induced15-LOX-1expressionandincreasedendogenous13-S-HODEproduct,insteadof15-S-HETEduringapoptosisingastriccancercellswithout15-LOX-1expressionbeforetreatmentbySC-236;(c)sc-236didn'teffectexpressionofCOX-1,COX-2,5-LOXand12-LOX;and(d)15-LOX-1inhibitionsuppressedSC-236inducedapoptosis.ThesefindingsdemonstratedthatSC-236inducedapoptosisingastriccancercellsviaup-regulationof25-LOX-1.Theyalsosupporttheconceptthatthelossoftheproapopoticroleof15-LOX-1inepithelialcancersisnotlimitedtohumancolorectalandesophagealcancers.
简介:继1996年幽门螺杆菌(H.pylori)感染处理的Maastricht共识会议后,欧洲H.pylori研究组(EHPSG)于2000年再次在荷兰Maastricht举行会议,对原先的Maastricht指南进行修订和更新.